Skip to main content

Interactions between N Ice Cherry and Seladelpar

1 drug interaction and 3 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Minor drug interactions

Minor:

menthol topical seladelpar

Applies to: N Ice Cherry (menthol topical) and seladelpar

Coadministration with orally administered menthol may decrease plasma concentrations of drugs that are substrates of the CYP450 3A4 and/or CYP450 2C9 isoenzymes. The proposed mechanism is increased clearance due to menthol-mediated induction of CYP450 3A4 and CYP450 2C9. In vivo data suggests that concomitant administration of oral menthol reduced the systemic exposure (AUC) of triazolam (a CYP450 3A4 substrate) by 40%, and phenytoin (a CYP450 2C9 substrate) by 20%. Until further data are available, no specific precautions are recommended.

References (4)
  1. (2024) "Product Information. Advil Targeted Relief (camphor/capsicum/menthol/methyl salicylate topical)." Haleon
  2. Hoshino M (2015) "Effects of menthol on the pharmacokinetics of triazolam and phenytoin." Biol Pharm Bull, 38, p. 454-60
  3. Hoshino M (2014) "Menthol reduces the anticoagulation effect of warfarin by cytochrome p450 2C expression." Eur J Pharm Sci, 56, p. 92-101
  4. (2019) "Product Information. Radian B Muscle Rub (camphor/capsicum/menthol/meth salic top)." Thornton & Ross Ltd

Food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Disease interactions

3 potential interactions Applies to: 3 conditions, including Hemodialysis, Liver Disease, and Biliary Obstruction.

Biliary Obstruction

Moderate:

seladelpar

Seladelpar has a moderate potential interaction with Biliary Obstruction.

Seladelpar should be avoided in patients with complete biliary obstruction. If biliary obstruction is suspected this drug should be interrupted and treatment started as clinically indicated.

Hemodialysis

Moderate:

seladelpar

Seladelpar has a moderate potential interaction with Hemodialysis.

The use of seladelpar in patients with end-stage renal disease undergoing dialysis has not been studied.

Liver Disease

Moderate:

seladelpar

Seladelpar has a moderate potential interaction with Liver Disease.

The safety and efficacy of seladelpar in patients with decompensated cirrhosis have not been established and its use is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy). No dose adjustment is recommended in patients with mild liver dysfunction, but discontinuation of treatment should be considered in any patients progressing to moderate or severe liver dysfunction (Child-Pugh B or C).

Report options

Loading...
QR code containing a link to this page

More resources

N Ice Cherry

A total of 364 drugs are known to interact with N Ice Cherry.

seladelpar

A total of 168 drugs are known to interact with seladelpar.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer